How ‘open source’ seed producers from the US to India are changing global food production

seeds

Editor’s note: This article originally appeared at Ensia

Frank Morton has been breeding lettuce since the 1980s. His company offers 114 varieties, among them Outredgeous, which last year became the first plant that NASA astronauts grew and ate in space. For nearly 20 years, Morton’s work was limited only by his imagination and by how many different kinds of lettuce he could get his hands on. But in the early 2000s, he started noticing more and more lettuces were patented, meaning he would not be able to use them for breeding. The patents weren’t just for different types of lettuce, but specific traits such as resistance to a disease, a particular shade of red or green, or curliness of the leaf. Such patents have increased in the years since, and are encroaching on a growing range of crops, from corn to carrots — a trend that has plant breeders, environmentalists and food security experts concerned about the future of the food production.

A determined fellow dedicated to the millennia-old tradition of plant breeding, Morton still breeds lettuce — it just takes longer, because more restrictions make it harder for him to do his work.

“It’s just a rock in the river and I’m floating around it. That’s basically what we have to do, but it breaks the breeding tradition,” he says. “I think these lettuce patents are overreaching and if they [were to hold up in court], nobody can breed a new lettuce anymore because all the traits have been claimed.” He continues to work with what is available, breeding for traits he desires while being extra careful to avoid any material restricted by intellectual property rights. He has also joined a movement that is growing in the U.S. and around the world: “open source” breeding.

If the term sounds like it belongs in the tech world more than in plant breeding, that’s no accident. The Open Source Seed Initiative, inspired by “the free and open source software movement that has provided alternatives to proprietary software,” was created to ensure that some plant varieties and genes will remain free from intellectual property rights and available for plant breeders in perpetuity. As part of the initiative, commonly known as OSSI, U.S. breeders can take a pledge that commits the seeds they produce to remain available for others to use for breeding in the future.

That doesn’t mean they can’t build a business with or sell them. What the pledge does is allow farmers who buy seeds from an open-source breeder to cross them with other material to breed their own varieties and save them for future seasons — two things many crop patents forbid. Dozens of breeders and seed companies have committed to OSSI since the initiative’s launch in 2014.

Compromised Future

For University of Wisconsin–Madison professor emeritus and OSSI board member Jack Kloppenburg, control of seeds and the ability to breed new crops are matters of both food security and environmental protection. Seeds play a role in larger issues like biodiversity, farmers’ rights, control of the food system and use of agricultural chemicals, which many independent breeders try to avoid or reduce by breeding natural resistance into crops themselves.

Kloppenburg emphasizes that the open-source movement is not about genetically modified organisms; patents can affect all crops, vegetable or grain, GMO or conventional, organic or not. “Control over the seed is what’s at the core of all environmental sustainability that we’re working toward,” he says, pointing to the increased consolidation in the global agriculture industry, most recently with the mergers announced between ChemChina and Syngenta in August 2016, and Monsanto and Bayer in September. “If you go to the farmer’s market and you’re interested in buying good, local, sustainably produced vegetables, you also need to understand that most vegetables are coming out of a breeding process that is itself endangered. We will not have food sovereignty until we have seed sovereignty.”

OSSI supporters argue that as planting material becomes more restricted through intellectual property rights, the future of the food supply is compromised because the gene pool is continually shrinking. OSSI executive director Claire Luby, whose Ph.D. thesis focused on genetic variation and availability within carrots, found that about one-third of all carrot material has been protected by intellectual property rights, rendering it unavailable or difficult for plant breeders to use. Similar estimates do not yet exist for other crops, but experts such as Luby are confident that big commodity crops such as corn are even more heavily impacted than crops such as lettuce and carrots.

A Matter of Perspective

Growers breed plants to selectively express desirable traits — from those that will improve a crop’s taste or color, to those that help crops thrive in certain environments and resist threats such as pests or disease. Opponents of crop-trait patents say the increase in patents is shrinking the catalog of plant material available to breeders at a time when the need for genetic diversity is greater than ever, thanks to the less-predictable conditions brought on by climate change.

In an email, Monsanto spokesperson Carly Scaduto recognized the importance of genetic diversity, saying it’s crucial for the company’s operations and Monsanto works to preserve diversity through its four gene banks and by collaborating with institutions around the world, including the U.S. Department of Agriculture. But she disagreed with the notion that intellectual property suppresses other breeding efforts. “Patents and [plant variety protection] inspire innovation,” she wrote. “Basically, the patent creates a map to allow anyone else to do the same once the patent expires. Oftentimes those ‘how to’ instructions enable others to accomplish the same result by finding another method to get there. So rather than hindering innovation, such protection facilitates it by placing more material and know-how in the public domain.”

Morton, however, argues waiting the 20 years for a patent to expire is no way to encourage innovation, and waiting that long to breed crops that can adapt to changing conditions is a losing battle. Even that misses the main point for Morton, though: genetic resources have always belonged to the commons, and should continue to be a public good, he says. “[Independent plant breeders] have neither the time nor money for such formalities, and monetary incentives are not what move us. We want to improve farming for farmers. That’s a different motivator, not promoted by stifling the free use of the best and newest genetic resources.”

Furthermore, Morton takes issue with the very concept of patenting a plant trait. “You didn’t actually create it,” he says. “The plant created it, and the plant breeder has no idea how the plant created that trait. It is just nature at work.”

For Carol Deppe, an Oregon plant breeder and OSSI board member, there’s another component to breeding that’s important. “When you breed a variety, you breed your own values right into the variety,” she says. “If you believe in huge agribusiness farms with monocultures that are managed with massive doses of herbicides, then you breed your concept of what agriculture should be like into that variety. I do exactly the opposite.”

While a handful of medium-sized companies (those with international markets but smaller than, say, Monsanto) hold patents, most smaller seed companies are able to survive without patenting — they either are opposed to the practice, have decided the process is too costly to be worthwhile, or both.

Morton argues that avoiding intellectual property protection also encourages more active breeding. “Seems to me that my incentive to crank out new stuff is stronger than [companies that patent]. I need new stuff constantly to feed my catalog with new material, knowing that my competitors will be selling my varieties within a few years,” he says. “A patent creates a 20-year insulation against competitive intrusion, which seems pretty cushy from my perspective.”

Global Response 

While the U.S. seems to be leading the open-source charge, the concept is rapidly spreading around the world. In India, the Centre for Sustainable Agriculture, which describes itself as a professional resource organization, runs an open-source seed program, working with farmers to preserve seeds for traditional food varieties and to involve them in breeding new varieties that meet specific needs. The organization also helps farmers access and market open-source seeds. German organization Agrecol is in the process of launching an open source “license,” essentially a more formal, legally binding version of the OSSI pledge for breeders in the European Union. (Regulations governing breeding differ from country to country, so the OSSI pledge cannot simply be adopted as-is in Europe or elsewhere.) In early November the European Commission, the EU’s executive body, declared that conventionally bred plants should be nonpatentable, marking a shift from the European Patent Office’s current stance, which permits patents for conventionally bred crops. The statement is not law, however; it will now be up to European governments to push the patent office to implement the commission’s statement.

In October 2016, the Dutch organization Hivos hosted a conference on open-source seed systems in Ethiopia, attracting farmers, community seed bank operators, and representatives of governments, non-governmental organizations and seed companies from around East Africa to learn about the open-source seed movement and the global shift toward patenting seeds.

Willy Douma, who runs Hivos’ open-source seed systems program, says the organization is in the process of building a global alliance on open-source seed systems that it hopes to launch formally next year. A coalition of environmental and development groups (including Hivos, international development nonprofit USC Canada and the Action Group on Erosion, Technology and Concentration) has compiled a database of seeds and biodiversity around the world to publish the Seed Map Project. And in a report published in September, the Global Alliance for the Future of Food — a collaboration of philanthropic foundations, including the WK Kellogg Foundation, the McKnight Foundation and more — said that to ensure a resilient food supply, farmers need to be able to access, exchange and improve seeds, and have a voice in shaping seed policies. The report also emphasized the role that diverse, local seed supplies play in sustainable food systems — a connection that Luby of OSSI hopes more people start to make soon.

“The food movement has focused on where is it grown and how is it grown, and the seed systems haven’t been as much a part of those conversations,” she says. “We’re trying to connect with people to say, ‘Hey, there’s an even deeper layer to your food.’”

This article originally appeared at Ensia and has been republished here with permission.

Rachel Cernansky is a freelance journalist who has contributed to numerous science and general media outlets. Follow her on Twitter @rachelcernansky

South Australia’s ban on GMO crops could be overturned as Liberal Party takes power

The victory by the Liberal Party in the South Australian election, may lead to a new era of choice for that state’s farmers.

Last year the Liberal Party committed to a review of a moratorium on growing genetically modified crops if it should win.

If it lifts the ban, Tasmania would be the last remaining grain growing state where GM crop can’t be grown. A four-year ban was lifted in Victoria in November 2007, paving the way for the first crops to be grown in 2008.

…

Grain Producers Australia is calling for an immediate exemption for the transport of GM seed through South Australia, in a bid to reduce seed costs to West Australian farmers.

…

WAFarmers Grains Council president Duncan Young said the ban on GM canola in WA was lifted in 2010.

“It’s positive — the fact that growers have a choice on whether to grow conventional, hybrid or GM,” Mr Young said.

“It’s great for integrated weed management.”

Mr Young said the new high omega 3 GM canola, which was approved by the Office of the Gene Technology Regulator for release in Australia, would be a game changer.

“This is the second phase of GM technology,” he said.

Read full, original post: Ten years of genetically modified crops

GMO labeling debate expected to heat up as USDA nears release of proposed rules

QR code food packag scan

Expect the debate over GMO labeling—the labeling of foods containing genetically modified ingredients—to heat up again in the near future.

USDA Under Secretary for Marketing and Regulatory Programs Greg Ibach tells Brownfield the agency is close to releasing a proposed GMO labeling rule for public comment.

“We’re done with our interagency approach to put out a proposed rule for labeling foods that have ingredients derived from genetic engineering,” Ibach says. “Now we’re having some interactions with other agencies in the federal government to make sure that we’re not crossing any lines that have to do with international trade or other regulations that are out there. And then we’ll be releasing those regulations for public comment.”

…

It’s … important the GMO labels do not raise any food safety concerns, Ibach says, and he indicates electronic labeling is part of the plan.

“I think the intent largely was for something on the package that gave an initial indication, and that there would be an openness for consumers to be able to delve deeper if they use the QC code, or different things like that.”

The bill mandating GMO labeling on food and beverage products was signed into law in 2016. Congress charged the USDA with developing the rules.

Read full, original post: USDA is close to releasing GMO labeling rules

Monsanto to fund gene editing company Pairwise Plants to develop new crop varieties

yx lfgb zcqimtbtyyat

Monsanto Co. will fund a new U.S. company that aims to develop crops using technology known as gene editing, rather than the genetic modification that helped it become the world’s biggest seed seller.

Monsanto’s vice president of global biotechnology, Tom Adams, will leave the seed giant to become chief executive of the new firm, called Pairwise Plants, the companies told Reuters. He steps into the new role on April 1.

Monsanto Growth Ventures, along with Deerfield Management, … announced the it had led a $25 million financing for San Diego-based Pairwise.

The collaboration accelerates a race among agricultural scientists and companies worldwide to develop new seeds for crops using gene editing, a process they say can produce non-GMO farm products that do not contain foreign DNA from a different species.

Unlike traditional GMOs, in which a gene is added from another organism, gene-editing works like the find-and-replace function on a word processor. It finds a gene and then makes changes by amending or deleting it.

Using “molecular scissors” to cut DNA means scientists can edit genomes more precisely and rapidly than ever before, and altered agricultural products could get to market more quickly and cheaply.

Read full, original post: Monsanto backs new company focused on gene editing, not GMOs

New online study of BRCA cancer risk in Ashkenazi Jews could provide new model for genetic testing

screening

A new study will provide free testing for three mutations that substantially increase the risk for developing breast, ovarian and prostate cancer among people with Eastern European Jewish ancestry.

The BRCA Founder Outreach Study (BFOR)…will test 4,000 men and women in four US cities — New York, Los Angeles, Philadelphia and Boston — for mutations in the BRCA gene that are more common among those with Ashkenazi Jewish ancestry. Those who test positive for one of the mutations will receive genetic counseling to figure out next steps.

…

But the study’s goal extends beyond cancer or Ashkenazi Jews, said [Dr. Kenneth Offit, who is serving on the study’s executive committee]…

“We think it’s a model for the future of genetic testing in health care,” he said.

…

What’s new about the way testing is conducted in the BFOR study, Offit said, is the fact that patients sign up online and can choose to receive their results from their primary care provider. The testing will be free for participants, and the study is open to anyone over 25 years old who has health insurance and at least one grandparent with Ashkenazi heritage.

…

“Yes, we will be testing many individuals of Ashkenazi background and we will save lives for sure because we know that,” he said, “but the research question is to improve the way we offer this information to the whole population.”

Read full, original post: New study on cancer risk in Ashkenazi Jews aims to be model for genetic testing

CRISPR opens the door on crop research by smaller companies and universities

CALS PlantScience

CRISPR, a new gene-editing technique, offers an end run around the cost associated with traditional genetic engineering, allowing smaller companies and public institutions to enter the market. Not only that, but crops with a market too small to be of interest to GM researchers are now in play.

Research is also being accelerated because the capital costs to participate are dropping. In 2001, it cost $100 million to sequence a genome. By 2015, the cost had declined to $1,000. The continuing decline in the cost of computing and cloud data storage has allowed small companies to maintain data sets that a decade ago could have been supported only by the Monsantos of the world.

…

CRISPR research is being done to increase yields, nutrients, and resistance to disease and pests, improve photosynthesis and drought tolerance, and develop plants that can thrive in a changing climate. Not all of these projects will be successful, and we’re a long way from a risk-based regulatory scheme that makes sense, but gene editing holds great promise.

…

It hardly seems necessary at this late date to point out the obvious, but I will anyway. Every regulatory agency in the world that has examined these breeding techniques has found them safe.

Read full, original post: CRISPR Will Make GMOs Ubiquitous

Men, women respond differently to genes linked to depression

Depression Men vs Women

In men and women diagnosed with major depressive disorder, the same genes show the opposite changes. In other words, the molecular underpinnings of depression in men and women may be different. That’s according to a new postmortem brain study published on [March 14] in the journal Biological Psychiatry. The study could in the future help lead to more effective treatments for depression, if it turns out that men and women need different types of treatment.

…

The study is significant for two reasons. For one, it is the first to suggest an opposing pathology for depression in men and women, which could eventually influence how depression is treated.

…

But the study also highlights the necessity of diversity in scientific study. Major depressive disorder affects women about twice as often as men. Women are also more likely to experience symptoms like weight gain along with depression, suggesting the biological mechanisms at work may be different. But many depression studies only look at men, and ones that look at both sexes do not necessarily differentiate between the two when reporting findings.

The science of genetics overwhelmingly suggests how similar we all really are. But it also underscores how much there is to gain from understanding and embracing how we are different.

Read full, original post: The Genetics of Depression Are Different for Men and Women

Animals with unique traits open window into understanding human diseases

c o

From a bat’s wings to an elephant’s cancer resistance, an interdisciplinary team of scientists at University of Utah Health are using animals’ unique traits to pinpoint regions of the human genome that might affect health.

…

The research team scoured the ‘junk’ sections of five animal genomes — elephant, hibernating bat, orca and dolphin, naked mole rat and thirteen-lined ground squirrel — to identify regions that evolved rapidly. The team identified thousands of accelerated regions in each animal genome.

…

The researchers identified elements in the:

  • elephant genome linked to DNA repair that could help in the study of cancer resistance;
  • bat genome linked to wing development that could help in the study of hand and feet abnormalities;
  • dolphin and orca genome linked to eye development that could help in the study of cornea development, as well as elements linked to adaptation to high pressure environments that could help in understanding blood clotting disorders;
  • thirteen-lined ground squirrel genome linked to coloration/pigmentation that could help in study of albinism and Leopard Syndrome; and
  • naked mole rat genome linked to eye development that could help in the study of glaucoma.

“This method allows us to shine a light on nature’s potential solutions to disease across the entire animal kingdom,” said co-author Joshua Schiffman, M.D.

https://youtu.be/1Ou4YClCHyk

Read full, original post: Mapping the Genome Jungle: Unique Animal Traits Could Offer Insight into Human Disease

Decades-old immunosuppressant drug rapamycin could extend life

lw gene

In the 1990s, pharmacologist Dave Sharp of the University of Texas’s Barshop Institute for Longevity and Aging Studies in San Antonio was studying mice with pituitary dwarfism—a condition in which the pituitary gland fails to make enough growth hormone for normal development. The puzzle, Sharp explains, was that research had shown that these hormone-deficient dwarf mice lived longer than normal mice. “I wondered, why is being small connected with longer life?” he says.

Yeast research led by molecular biologist Michael Hall at the University of Basel in Switzerland was to provide Sharp with an unexpected lead. In 1996, a team led by Hall (who would go on to win a Lasker award in 2017 for the work) revealed a new intracellular signaling pathway, mediated by the protein targets of a compound called rapamycin.

Rapamycin, a compound first identified in the 1970s in a soil sample from Easter Island, has been used for decades to suppress the immune system in transplant patients; it seemed counterintuitive that it could prolong life, [pharmacologist Dave] Sharp notes. “Nobody would read my proposals,” he says. “They’d just laugh. You know, ‘An immunosuppressant extending lifespan?’” But research since then has lent support to Sharp’s theory.

Read full, original post: Could Rapamycin Help Humans Live Longer?

Viewpoint: Rampant anti-GMO beliefs make it more difficult to combat hunger and food insecurity

somalis apfarahabdiwarsameh

The negative rhetoric surrounding GMOs, big ag and non-organic food production is due for a reckoning. At some point, many will have to wake up to the reality that their beliefs on food are less rational than they are ideological. And that, in some cases, these beliefs are slowing food production worldwide.

“If we continue to make it hard for farmers to maintain production, we will have to accept a little more hunger and more food insecurity,” said food and agricultural economist Jayson Lusk, speaking at an Agvocacy Forum in Anaheim, Calif.

Many of these beliefs seem like philosophical, almost religious, responses cloaked in baseless accusations of what are real, tangible and very practical and needed advancements for agriculture and food production.\

“The average consumer may believe that organic is better, but that same person wants his or her tomatoes to last on the counter for an entire week,” said Juan Sabater, a tomato farmer in California.

…

Public perception can close doors. And it has. Researchers won’t pursue projects that have no support, regardless of how beneficial the advancement could be to the global food market.

Editor’s note: Toban Dyck is a farmer and Director of Communications at Manitoba Pulse & Soybean Growers

Read full, original post: Ripe for a rethink: Why the anti-GMO crowd can’t have it both ways

Ancient DNA from mysterious culture highlights North Africa’s role as ‘important crossroads’

About 15,000 years ago, in the oldest known cemetery in the world, people buried their dead in sitting positions with beads and animal horns, deep in a cave in what is now Morocco. These people were also found with small, sophisticated stone arrowheads and points, and 20th century archaeologists assumed they were part of an advanced European culture that had migrated across the Mediterranean Sea to North Africa. But now, their ancient DNA—the oldest ever obtained from Africans—shows that these people had no European ancestry. Instead, they were related to both Middle Easterners and sub-Saharan Africans, suggesting that more people were migrating in and out of North Africa than previously believed.

“The findings are really exciting,” says evolutionary geneticist Sarah Tishkoff of the University of Pennsylvania, who was not part of the work. One big surprise from the DNA, she says, is that it shows that “North Africa has been an important crossroads … for a lot longer than people thought.”

…

“It’s a thrill to look for the first time at ancient DNA from prehistoric peoples from North Africa, a place where repeated waves of migration have made reconstruction of the deep population history based on living populations almost impossible,” says population geneticist David Reich of Harvard University, who was not part of the team.

Read full, original post: Oldest DNA from Africa offers clues to mysterious ancient culture

Nigeria needs GMO seeds to feed growing population, says nation’s top scientist

ca

Nigerian scientists are drumming up support for modern agricultural biotechnology, saying the country cannot feed its growing population with the current conventional method of farming.

In an exclusive interview with the Alliance, Nigeria Academy of Science President Mosto Onuoha said the current method of farming would not sustain the nation and its people in years to come.

…

Prof. Onuoha argued that modern agricultural biotechnology holds the key to the nation’s future food security, saying it has the ability to help the nation grow better seeds that are resistant to pests and diseases, and able to combat the harmful effects of climate change while reducing the use of pesticides.

According to him, genetically engineered seeds will help farmers get good yield, which can guarantee food security for the nation in the future.

“Feeding our people in the next generation cannot be done the way we’re doing now,” he said. “Science has the ability, the right seeds even, to combat the bad effects of climate change — the adaptation is science that will be used.”

…

He urged government at all levels to invest in the future by looking at long-term plans that would guarantee the nation’s food security.

Read full, original post: NAS: Conventional ag won’t feed Nigeria

Is artificial intelligence a threat to our existence?

Unknown

I found myself seated among a group of physicists, astrologists, historians, philosophers, technologists, and futurists of various varieties and pedigrees. Given the august and diverse group, I decided to ask a provocative question.

…

In short, would artificial intelligence lead to the end of the human race?

…

I was stunned by two aspects of their response. First, no one at the table appeared taken aback, surprised, or flummoxed by the question. Second, they all answered immediately, and in unison, “yes.

…

One common fear among technologists is what could happen if Vladimir Putin or Kim Jong Il used software to shut off our power grid, decimating our food supply, heat, and logistical network.

…

[W]hat if an adversarial foreign government made the fake news that infected the 2016 cycle seem quaint by comparison. One day, after all, technology will possibly allow a hostile nation to create fake content that perfectly depicts, perhaps, a CNN or Fox News telecast (down to the anchors’ facial tics) instructing American citizens that a revolution is happening in the streets.

…

But, not everyone should sit there rocking back-and-forth stressing about a robot knocking down their front door. [Scientist Kevin] Kelly likened the threat level to that of an asteroid hitting earth: while it’s possible, and it could happen, it’s mathematically unlikely.

Read full, original post: “Should we be worried?”: Tech geniuses fret that A.I. is gonna kill us all – soonish

Did the EPA and Monsanto conspire to hide glyphosate’s health risks?

large
The Sacramento Bee recently ran an op-ed by Nathan Donley telling Americans: Don’t let EPA and Monsanto hide the truth on Roundup. As its conspiratorial headline suggests, Donley’s article is a mess of half-truths and bad science designed to fool readers into believing that the popular herbicide Roundup is dangerous.

The Bee declined to publish a rebuttal. I’d like to set the record straight here: Glyphosate, the active ingredient in Roundup, is perfectly safe when used as directed.

Donley began his piece with the claim that Monsanto has waged a 40-year campaign “to discredit research indicating the pesticide is a carcinogen.” The company succeeded, Donley wrote, because the U.S. EPA just recently concluded that glyphosate doesn’t cause cancer.

It’s true that the biotech giant has vigorously defended its flagship weed control product––but so has the world’s leading independent science bodies, including regulatory agencies in North America, Europe, Asia and Australia/New Zealand. Every scientific, regulatory, or health body that has independently reviewed the voluminous literature on glyphosate’s toxicity has declared that glyphosate is safe when used according to its label––except one as I’ll discuss below.

monsanto 2 6 18 2Most recently, the US Environmental Protection Agency released its glyphosate assessment (full assessment and supporting documents here), widely believed to be the most comprehensive review of the controversial herbicide ever, concluding:

The draft human health risk assessment concludes that glyphosate is not likely to be carcinogenic to humans.  The Agency’s assessment found no other meaningful risks to human health when the product is used according to the pesticide label.  The Agency’s scientific findings are consistent with the conclusions of science reviews by a number of other countries as well as the 2017 National Institute of Health Agricultural Health Survey.

Parenthetically, Donley hinted at how dubious his case was when he contended that 300 millions pounds of the herbicide have been “dumped” on farms and gardens across America. Actually, glyphosate is used in tiny amounts per acre, as this article in the Genetic Literacy Project by farmer David Walton makes clear. Considering its ubiquity and supposed danger, why don’t we all have cancer? There’s simply no way such a popular product could escape the scrutiny of independent experts, most of whom aren’t very fond of corporations anyway.

“The most rigorous analysis”

So, if the expert consensus tells us that glyphosate is safe, what facts can Donley muster that suggest that glyphosate poses serious health risks? What is “the most rigorous analysis of independent, peer-reviewed research” that Donley refers to? Donley is referencing a hazard analysis issued in 2015 by the International Agency for Research on Cancer (IARC), which is a semi-autonomous arm of the World Health Organization. While three WHO agencies have issued reports underscoring the consensus that glyphosate is safe as used, IARC, alone, issued a monograph that declared glyphosate a “probable human carcinogen” when used by agricultural workers. Note that the agency did not say glyphosate was a ‘probable human carcinogen’ in trace amounts in food or that it poses any genuine risks.

Why is there such a discrepancy between the IARC hazard findings and risk assessments of the regulatory and mainstream science communities? Many people misunderstand how IARC and its findings are perceived in the global regulatory framework. For more than 40 years, the agency has assessed 989 substances and activities, ranging from arsenic to sunbathing hairdressing; it’s found only one was “probably not” likely to cause cancer in humans. But scientists and regulators have pushed back after the finding; almost any substance can be judged toxic, even water, if the ‘dose’ is extreme and the exposure time is long enough.

Most scientists believe IARC’s hazard assessments are confusing to the public and the science community, and offer confusing regulatory guidance, noting for example that the sub-group also considers grapefruit juice, being a hairdresser and working the night shift to be as hazardous as glyphosate. Even more dangerous, in the organization’s opinion, are processed meat, sunlight, oral contraceptives, Chinese-style salted fish and alcohol–on the level of exposure to plutonium, based on its hazard

monsanto 2 6 18 3 Donley also doesn’t mention that Congress, because the United States has been a major funder, is investigating IARC for corruption. The press has been awash in reports that IARC deliberately excluded reviewing studies that didn’t fit the panels conclusion, which makes it appear predetermined. It should be noted that IARC does no research, it only reviews published research that it determines are appropriate, so if key studies were omitted its key conclusions are highly suspect. Moreover, one of the IARC experts involved in the monograph’s production, Christopher Portier, was paid $160,000 by lawyers who were planning to sue Monsanto once the agency’s report was released. Not even mentioning these serious charges, Donley called IARC’s work “the gold standard for cancer research.” Independent cancer researchers, however, argue that IARC’s methods are “outmoded and serve neither science nor society.”

Ideology over facts

After shamelessly repeating dozens of myths about Roundup, Donley concludes his article with that assertion “that Monsanto and the Scott Pruitt-led EPA want no part of a truly independent scientific process.” But evaluation of dozens of independent reports over 20 years match the Monsanto-Pruitt conclusion, as well as the consensus safety assessment reached under the Obama Administration in 2016 by 13 prominent independent scientists, which concluded:

…there is not strong support for the “suggestive evidence of carcinogenic potential” cancer classification descriptor based on the weight-of-evidence, which includes the fact that even small, non-statistically significant changes observed in animal carcinogenicity and epidemiological studies were contradicted by studies of equal or higher quality. The strongest support is for “not likely to be carcinogenic to humans” at the doses relevant to human health risk assessment for glyphosate.

How could Donley be so wrong? After all, he has a Ph.D. in cellular biology. My best guess is that he’s an ideologue whose worldview trumps the evidence. It’s worth noting that Donley’s arguments appear to be lifted almost entirely out of U.S. Right to Know’s (USRTK) playbook. In case you’re unaware, USRTK is funded by the Organic Consumers Association, which is virulently anti-GMO and anti-vaccine, and supports fringe health notions like homeopathy. [Read the Genetic Literacy Project profile here.]

Corporations aren’t perfect, and I have not hesitated to criticize big biotech firms in the past for missteps or malfeasance. However, there is no corporate conspiracy to conceal the risks posed by Roundup. Someone in this debate is ignoring independent science. And it isn’t Monsanto.

Cameron English is a freelance science writer and podcast host. He covers nutrition, public health, biotechnology and occasionally other topics. Visit his website and follow him on Twitter @CamWritesSoGood.

A version of this article originally appeared at RealClearScience as Quit the Glyphosate Conspiracy Theories and has been republished here with permission.

Why the body’s response to pregnancy may help us better understand cancer

pregnant

Svetomir Markovic knew something was different. Sometime around 2010, a fellow scientist at the Mayo Clinic had agreed to donate her healthy blood for use in the research laboratory where Markovic studies the interface between cancer and the immune system. In previous testing of the woman’s blood, her immune cells functioned normally. But then something changed, and nobody knew why.

“We thought our assays weren’t working,” recalls Markovic, a hematologist and oncologist whose research focuses on developing immunotherapies for melanoma and non-Hodgkin’s lymphoma. Or perhaps the reagents had expired, or the laboratory’s machines needed fine-tuning. For nearly a month, the team puzzled over the woman’s changing lab values. “At this point, she was quite visibly pregnant,” Markovic laughs, noting how obvious the answer seems in hindsight. “It finally dawned on me — what if it’s the pregnancy?”

Sensing that the question’s answer could have implications for his cancer research, Markovic decided to study cells of the placenta, the disk-shaped organ that develops during pregnancy and connects the mother’s blood supply with that of her fetus. In the eight years since then, Markovic and other researchers have discovered some remarkable similarities in how cancer cells and placental cells regulate the immune system. This knowledge may one day lead to better cancer detection and treatment. For now, though, researchers are focused on deciphering the underlying process — and answering a sobering question: Are the cells of death exploiting the mechanisms intended to promote the cells of life?

Typically, when the body senses a foreign substance such as a virus or a bacterium, it sends immune cells to attack the invader while also bolstering the immune system as a whole. Cancer cells are vulnerable to this kind of attack because they produce mutated proteins that the immune system may identify as foreign. But cancer cells can escape immune surveillance using a variety of techniques to disguise themselves.

undark logoUntil recently, Markovic says, most scientists believed that outside of localized changes near the cancer cells, the immune system of cancer patients essentially functioned normally. But as a young researcher in the early 2000s, he wasn’t convinced this told the whole story. He tested that idea by comparing immune-cell activity in the blood of healthy people and cancer patients.

What he found was that cancer doesn’t merely disrupt the immune response around the tumor — it affects the entire system. One of his team’s early findings, published in 2011, was that tumors have high levels of a particular protein known to suppress the immune system and induce a state of system-wide chronic inflammation. He says in his experiments, the immune system “was totally unable to fight.” What’s more, it became increasingly protective of cancer cells. He wondered: “How could a tiny cancer cell cause such dysfunction across the whole body’s immune system?”

Markovic theorized that tumors train the immune system to tolerate their foreign protein, though he wasn’t sure how until the pregnant researcher’s blood got him thinking. Researchers already knew that a woman’s immune system changes during pregnancy. Perhaps these changes could help explain what happens during cancer.

Like tumor cells, fetal cells are foreign to the body. Half of their genes come from another source (and in the case of donor eggs or embryos, all of the genes are foreign). If an organ this incompatible were transplanted into the body, it would likely be rejected. But during pregnancy, the fetus is protected from the mother’s immune system by the placenta, which has specialized cells — called trophoblasts — that can burrow into the mother’s body without exciting an attack by the immune system.

During pregnancy, a mother’s immune system isn’t switched off, but it is strategically suppressed, especially during the first trimester to allow for successful implantation. A subset of immune cells that manage immune system suppression, known as regulatory T cells, begins learning to tolerate the fetal cells as non-foreign. Stanford researchers recently discovered that the changes in an expectant mother’s immune system follow a specific timeline in full-term pregnancies, which they dubbed an “immunological clock of pregnancy.” Interestingly, as the clock progresses, regulatory T cells become increasingly able to tolerate fetal cells.

Markovic and his team at the Mayo Clinic wondered if tumors might be employing some of the same tactics as the placenta to outsmart the immune system: “Tumor cells may mimic trophoblastic cells of the placenta in that they downregulate danger signals while increasing expression of immunosuppressive mediators,” Markovic and his co-authors wrote in a 2015 review paper published in the journal Frontiers in Immunology. So he and his team compared the top 20 to 30 known immune system regulators in pregnancy with cancer’s immune system regulators.

“I nearly fell off my chair when I saw the data,” Markovic says. “There was such a profound similarity in regulation of the immune system by the placenta and by cancer. They were the exact same players doing the exact same thing.”

In particular, two molecules known to play a role in cancer’s suppression of the immune system are PD-L1 and galectin-9. They inhibit the abilities of tumor-infiltrating white blood cells and increase the abilities of immunosuppressive regulatory T cells. PD-L1 sits on the surface of cells and acts as a kind of stop sign, telling T cells not to attack. To gauge the dampening of the whole immune system, Markovic and his team tested levels of galectin-9 and PD-L1 in the blood plasma of pregnant women and of cancer patients. To determine local immune control, where the invasive tissue interfaces with normal cells, post-birth placentas and stage-four melanoma tumors were examined.

When compared with the blood of healthy, non-pregnant control subjects, galectin-9 levels in both pregnant women and cancer patients were significantly elevated. Similarly, PD-L1 levels were raised in both groups. In the local areas — the trophoblastic cells of the placenta and the edges of the tumor — both molecules were found at high concentrations. In a 2016 study published in the journal Placenta, Markovic’s team concludes that there are indeed “striking similarities between trophoblasts and tumors.”

cancer 2 13 18 2Of course the immune cells in the pregnant scientist’s blood had stopped behaving “normally”: the immune system in pregnancy is anything but normal.

This realization “pushed one entire laboratory project in the direction of understanding the immunology of pregnancy as a model for immunity of cancer,” Markovic says. One of his students went on to pursue a Ph.D. on this topic.

Markovic is not alone. Researchers at other institutions are also uncovering parallels between pregnancy and cancer. In both conditions, the immune system does not merely ignore the invasive cells, it actively encourages their growth. Scientists at the Rosalind Franklin University of Medicine and Science in Chicago found a “remarkable similarity” between the cells that support the growth and development in placentas and in tumors. They do this “by activating the portion of the immune response which initiates and helps control tissue repair,” the researchers note in the June 2017 issue of Gynecologic Oncology.

Scientists at the University of Otago in New Zealand have also noted that this altered immune function occurs when a certain set of genes is turned on or off. “Essentially, we are using the human placenta as a model to identify genes that play a key role in invasion in both the placenta and cancer,” wrote Chi Sutherland, a Ph.D. candidate leading the project, in an email.

“There is an increasing body of evidence in support of functional and molecular similarities between the placenta and cancer; however, no one has looked at the particular class of genes that we are interested in,” she added.

Sutherland is looking at a subset of genes known as retrotransposon-derived genes (RDGs). In the placenta, RDGs have been found working in pathways associated with many of the tools of invasion: immune suppression, blood vessel growth, cell proliferation, and inflammation.

Among mammals, the human placenta mounts one of the most extensive invasions of the uterine wall. This high level of interaction makes nutrient and waste transfer between mother and fetus more efficient, but it also risks provoking a stronger maternal immune response.

During conception and fetal development, the invasion process is amazingly complex and intricately regulated, explains Sutherland. In cancer, that regulation is lost. “We think that these genes, which are normally only expressed in the placenta to facilitate invasion, are becoming reactivated in cancer cells and supporting invasion in this context too,” she says. Her project aims to identify more placental RDGs and determine whether they are also activated in cancer cells, and if so, whether they promote cancer cell invasion.

cancer 2 13 18 3“We think some of these genes could be ‘hijacked’ by cancer cells and may contribute to the shared invasive characteristics of the placenta and cancer,” Sutherland says. If this is the case, then cancer cells do, in fact, exploit the very mechanisms that make it possible for a fetus to survive inside a woman’s womb.

Currently, several medications that inhibit PD-L1 are used in cancer immunotherapy. The problem is that when T cells are allowed to attack, they can destroy both cancer cells and healthy cells, leading to a wide array of side effects. Sutherland says the genes she studies are already silenced in healthy adult tissue, so theoretically researchers should be able to design therapies that re-silence them in cancer cells without side effects.

For his part, Markovic plans to research diseases of the placenta, to see whether there is an on/off switch for its control of the immune system. He is hopeful that if better understood, these biological mechanisms could illuminate new ways of treating cancer. As of today, his team has one “candidate molecule” that they hope to bring into clinical studies within the next 18 months, and a second one that is showing great promise.

And of course, it is not lost on Markovic — and certainly not on his wife, he says — that this promising line of inquiry might never have been explored, had that female colleague not been working as a medical research scientist at the Mayo clinic eight years back; had she not volunteered to donate her blood for Markovic’s research; and had she not continued to work — and donate — after becoming pregnant.

When Markovic told his wife, a cardiologist, about his discovery of the striking similarities between how tumors and placentas control the immune system, he describes her as being wholly unsurprised.

“See?” Markovic recalls her replying. “Women had the answer all along.”

Olivia Campbell, a science journalist and essayist, is a regular contributor at New York Magazine. Her work has also appeared in The Washington Post, Scientific American, Quartz, VICE, Pacific Standard, and STAT News. Twitter: @liviecampbell. 

This article was originally published on Undark as Can Pregnancy Help Scientists Better Understand Cancer? and has been republished here with permission.

Indian seed companies threaten to halt supply of GMO Bt insect-resistant cotton seeds over price cut

india cotton

Indian seed companies threatened … to halt supplies to 8 million cotton farmers in protest against a potential government plan to cut prices by 7.5 per cent, the chief of a producers’ body said.

…

New Delhi is likely to lower the price of genetically modified (GM) cotton seeds by 7.5 per cent to 740 rupees ($11) for 450 grams of seeds to help farmers whose fields have been ravaged by pests.

…

Other than cutting the prices of GM cotton seeds, India is likely to impose another cut to Monsanto Co’s royalties paid by domestic companies for its GM cotton seeds.

The latest reduction risks another row with the US company, the world’s biggest seed maker, which threatened to leave India in 2016 when the government cut its royalties by more than 70 per cent.

In 2017/18 India’s cotton output is set to rise by 9.3 per cent but still short of the record high predicted by industry analysts because boll worm caused damage in some regions.

New Delhi approved the first GM cotton seed trait in 2003 and an upgraded variety in 2006, helping to transform the country into the world’s top producer of the fibre.

Read full, original post: Cotton seed firms threaten to halt supply to 8 mn farmers over price cut

How to avert an ‘antibiotic apocalypse’

resist

The “Antibiotic Apocalypse” scenario, where drug-resistant bacteria end humanity, often seems to be somewhat inevitable, a process driven so strongly by the vast powers of industries such as agriculture and healthcare that humanity might as well lie down and let a tide of invincible bacteria rise off kitchen surfaces to smother us all.

Back in pragmatic reality, scientists are coming up with ever-more ingenious ways to combat the growing threat, exemplified by a recent paper from researchers at the European Molecular Biology Laboratory (EMBL). The authors have determined the molecular origin of a mechanism bacteria use to transfer resistance genes that fuels the rapid spread of resistance.

…

Senior author and research leader Orsolya Barabas explained how the protein facilitates the spread of genes: “If you think of ropes or wires, they are usually bundled and wound-up to make them stronger. If you want to tear or cut one, it’s much easier if you unwind and loosen it first,” says Barabas, “It’s the same for DNA, and the transposon transfer mechanism takes advantage of this.”

…

The potential for this research is huge, as Barabas explains: “Our discoveries will allow us to design improved diagnostic and preventive approaches, so as to better control the spread of antibiotic resistance genes. In addition, these insights can allow us to discover strategies to block resistance transfer, and our current study already provides proof-of-principle for this. Such strategies could, for example, help prevent resistance transfer in people diagnosed as carriers of antibiotic resistant bacteria.”

Editor’s note: Read the full study

Read full, original post: Averting the Antibiotic Resistance Apocalypse

Staying ‘highly physically fit’ could stave off dementia by nearly 90%

cycling

The intricacies behind what can cause dementia are still largely a mystery and highly debated. But a new study published [March 14] in Neurology offers more evidence that staying fit can keep both our bodies and minds sharp into our later years.

Swedish researchers pored through data from an ongoing project that first began in 1968, the Prospective Population Study of Women in Göteborg. More than 1,400 Swedish women from the ages of 38 to 60 were interviewed and medically examined, then had their health periodically tracked for the next several decades…

From 1968 to 2012, 44 of these women had been diagnosed with some form of dementia, most often Alzheimer’s disease. But women who had been categorized as highly fit—40 in total—were much less likely to develop it…

The researchers estimated that highly fit women were 88 percent less likely to develop dementia than even moderately fit women…

“These findings are exciting because it’s possible that improving people’s cardiovascular fitness in middle age could delay or even prevent them from developing dementia,” said study author Helena Hörder, a researcher at the University of Gothenburg, in a statement.

The study isn’t the first of its kind to suggest that exercise can stave off dementia, though it might be the longest-spanning one…But these studies can’t tell us directly whether exercise is a key driver of preventing dementia, Hörder said.

Read full, original post: Physically Fit Women Were Almost 90% Less Likely to Get Dementia in 44-Year-Study